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Introduction
Animal models are believed to be predictive for drug devel-
opment in human health care. While LD50 studies of drug
candidates have always been performed in animals like
rodents or dogs, efficacy and adverse effect studies using
animals as a model for humans were prompted only in the
late 1950s, as a consequence of the thalidomide scandal,
where thousands of babies were born with severe extremity
deformations.
In the last 10–15 years, preclinical research methodolo-
gies have increased crucially regarding measurement of
sensitivity and specificity. Adapted and improved for dedi-
cated use in animal research, positron emission tomography
(PET) and single photon emission computed tomography
(SPECT) are good examples of such methodologies. It
seems to us that increased measurement precision in animal
research has somewhat raised expectations regarding human
outcome prediction of preclinical data.
In recent years, on the other hand, there has been increas-
ing scepticism about the essentiality of animal models for
medical progress [1–7]. Statements like “virtually every
achievement of the last century has depended directly or
indirectly on the research with animals” are often found in
the literature to emphasize the importance and necessity of
animal models used in drug development and medical sci-
ence. Robert Matthews [6] discussed the validity of this
particular statement in a critical article in 2008 and con-
cluded that this statement is anecdotal and does not gener-
ally hold true. He is convinced, though, and surely there is
evidence that “animal models can and have provided many
crucial insights that have led to major advances in medicine
and surgery”. Hence, he claims that systematic investiga-
tions on the use of animal models and on the evidence that
they possibly can provide are necessary.
Gill Langley, in her critical paper in 2009, referred to the
same statement as Matthews a year earlier [7]. Langley
concluded that relying on animal surrogates of human ill-
nesses is a flawed approach in science. Her own investiga-
tions, as well as several published systematic reviews of the
reliability of animal models, have shown that fewer than
50 % of animal studies have predicted human outcomes
sufficiently. In certain fields of research, e.g. vaccination
development against acquired immunodeficiency syndrome
(AIDS), prediction failure of chimpanzee and macaque
models is 100 % [7, 8].
We are convinced that animal models can be useful tools
in biomedical research, but undoubtedly, it has frequently
been observed that effects found in animal models cannot be
translated to the clinic.
Translation problems
Sena and colleagues reported only three interventions for
acute ischaemic stroke treatment with a convincing effect in
patients out of 494 interventions that showed a positive
effect in animal models [9]. They have tried to identify
reasons for this tremendous discrepancy between preclinical
animal studies and patient studies in the clinic. The first
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category of reasons for the discrepancy is specific for exper-
imental stroke studies, such as schedule of treatment, the co-
administration of neuroprotective anaesthetics or the animal
models themselves. Animals used in experimental stroke
research are mostly young and healthy, whereas patients
are often elderly with comorbidities like diabetes and hyper-
tension. Furthermore, in animal studies, time to treatment
was often as short as 10 min. Patients for clinical trials, on
the other hand, were treated up to 24 h after stroke onset [9].
For many diseases, underlying mechanisms are
unknown, which makes it rather difficult to develop repre-
sentative animal models. Animal models, therefore, are
often designed according to observed disease symptoms or
show disease phenotypes differing crucially from human
ones if underlying mechanisms are being reproduced genet-
ically [7]. A prominent example is the genetic modification
of mice to develop human cystic fibrosis in the early 1990s.
Unexpectedly, mice showed different symptoms from
human patients [10]. A more recent example of non-
predictive animal models was described by Ebos et al. in
the field of angiogenesis inhibiting agent development
against different types of cancer [11]. The authors describe
how short-term application of anti-angiogenesis drugs, such
as sunitinib, leads to increased metastasis in animal models
and consequently to a reduced median survival compared to
vehicle-treated groups. In contrast to these findings stand
encouraging results after applying sustained sunitinib treat-
ment to animal models with preestablished tumours. This
initial research, though, has not considered potential evasion
mechanisms of cancer cells as a consequence of drug treat-
ment. The sunitinib example illustrates that drawing con-
clusions from non-predictive animal models—apart from
wasting research funding and animal lives—might expose
patients to unnecessary risk.
The second category of discrepancy reasons discussed by
Sena et al. is a more general issue. Animal studies often
seem to lack certain aspects of study design which are fully
established in clinical trials, e.g. randomization of test sub-
jects to treatment or control groups, blinded performance of
treatment and blinded assessment of outcome. Such study
design aspects seem to lead to overestimated drug efficacy
in preclinical animal research if neglected [4, 9, 12–14].
Underpowered studies
For a scientific efficacy confirmation of drug candidates or
other medical interventions, statistical testing is performed to
identify significant differences between test groups. For pub-
lication of biomedical research data, most journal editors and
peer reviewers request statistical significance of results. The
sense and suitability of this practice has often been criticized
[15, 16], but this topic will not be elaborated here in further
detail. In fact, statistical significance is dependent mainly on
the underlying null hypothesis, the sample size, the variance
of the data and the significance level alpha, which in most
cases is taken as the 5 % limit somewhat arbitrarily introduced
by Ronald Fisher. Generally speaking, the bigger the group
size, the easier it gets to find statistical differences between
two test groups. Or similarly, the more homogeneous the test
groups, the higher the chance to find statistical differences
between the groups for reasons of decreased data variance.
In order to reliably find significant differences between
test groups, it is necessary to carefully determine the size of
a relevant effect and estimate the expected variance of the
data. Based on these two parameters (minimal effect size
and variance) it is possible to calculate the minimal size of
test groups required to detect statistical differences with a
certain probability. This probability is referred to as the
power or sensitivity of the study and by convention should
be at least 80–90 %. Systematic reviewing of preclinical
stroke data has shown that such considerations together with
sample size calculation in the planning phase of a study are
hardly ever performed [9, 12]. In preclinical animal research
in general, ethical concerns, deservedly so, play an impor-
tant role. Group sizes in animal experimentation are there-
fore requested by authorities to be kept as small as possible.
As a consequence, many studies report small animal group
sizes. Such studies are often underpowered, as it is not
possible to reliably detect group differences with high
enough probability. Results of underpowered studies are in
fact useless and therefore just as unethical as using more
animals per experiment than necessary.
For medical progress it is essential that experiments yield
reliable data. Results need to be externally valid for success-
ful extrapolation from the bench to the bedside. Underpow-
ered studies in this regard suffer from a major problem: the
chance to detect valid effects is too low to be reliable in any
kind. In an attempt to outweigh power problems due to
small group sizes, test parameters, including test animals,
are usually standardized as much as possible to reduce data
variance, e.g. test animals are often inbred. It is widely
assumed that such strict standardizations increase the repro-
ducibility and therefore the reliability of research data [17].
Standardization fallacy
Several years ago, Crabbe et al. tried to test reproducibility
of experimental animal data by comparing behavioural tests
performed in different laboratories in North America [18].
The researchers tried to strictly standardize all possible
parameters of their experiments they could think of between
these laboratories. Animals were for example shipped on the
same day from the same supplier or experimenters wore
gloves of the same kind in all three laboratories. Mice of
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different strains underwent several behavioural tests, e.g.
either after cocaine or vehicle injection. Crabbe and his
colleagues were assuming that in such a maximally stand-
ardized setup reproducibility of results should be very high.
Surprisingly, this was not the case, as they found large
effects of site in mouse behaviour. Especially small genetic
effects turned out to be strongly influenced by environmen-
tal factors and animal handling. Wahlsten and colleagues
concluded in a follow-up article that it might be impossible
to adjust the laboratory environment so that it is sufficiently
similar between facilities to guarantee highest possible
reproducibility of results [19]. In another study including
multiple laboratories, Richter and colleagues tried to inves-
tigate whether strict standardization of experimental param-
eters beneficially affects reproducibility of mouse behaviour
[17]. They retrospectively regrouped test animals into
“pseudo-heterogenized” groups and compared the observed
behavioural strain differences with the original strictly
standardized samples in terms of false-positive result detec-
tion, i.e. non-reproducible results with no external validity.
Richter and coworkers concluded that overly strict stand-
ardization of environmental parameters might lead to spu-
rious results with no external validity. This had earlier been
referred to as the “standardization fallacy” [20]. The authors
therefore suggest that adequate environmental heterogeniza-
tion of such factors might improve reproducibility of results.
They later confirmed their results empirically [21].
Translational research in nuclear medicine
The question arises now to what extent such problems also
apply to the field of nuclear medicine and molecular imag-
ing. It can be argued that mouse behaviour might be less
robustly measured than the distribution of a PET tracer in
the mouse body. Furthermore, it is well conceivable that
mouse behaviour, as an enormously complex outcome
measure, might be more prone to environmental influences
than the uptake of a specific PET tracer into tumour tissue of
mice. In an attempt to extrapolate the study design of
Richter and colleagues to the field of small animal PET,
we recently performed a pilot study to investigate the impact
of strict standardization on the generation of false-positive
results [22]. We assessed 18F-fluorodeoxyglucose (FDG)
tissue uptake differences between male and female NMRI
mice. A statistically significant confirmation of the Richter
study was not possible, presumably due to small study
power, but we found a clear trend towards higher false-
positive rates under strictly standardized experimental con-
ditions compared to pseudo-heterogenized ones. Further-
more, we tried to assess the inherent variability of 18F-
FDG brain uptake in SD rats under highly standardized
conditions. We determined uptake variability within animals
using a test-retest approach, as well as uptake variability
between different individuals of the same test group (intra-
vs inter-animal variability). Contrary to our assumptions that
intra-animal variability would be essentially smaller than
inter-individual variability, we found that both types of
variability were in the same range. Despite the small scale
of our study and hence the resultant shortcomings, the data
affirm that reproducibility of animal experiments is a prob-
lem in nuclear medicine as well as in behavioural mouse
research and we are convinced that further research in this
regard seems worthwhile. In addition, we believe that the
development of new interventions in nuclear therapy or
diagnostics might suffer from translation problems similar
to drug development in acute stroke, which was reported by
Sena and colleagues [9]. Even though to our knowledge
never formally investigated, it seems conceivable that a
substantial fraction of preclinical animal data in the field
of molecular imaging might be misleading. Exemplarily, the
development of a new PET tracer for pancreatic tumour
diagnosis shall be considered. In the majority of in vivo
proof of principle research, mice with subcutaneously ino-
culated pancreas tumour xenografts are investigated. Such
tumours grow, isolated from their usually occurring stromal
surrounding, at a well-exposed body part, e.g. the shoulder.
It seems logical that a PET scan visualizes even rather small
effects of tumour uptake, as the tumour surrounding pre-
sumably does not accumulate enough radiotracer to dimin-
ish the contrast of tumour uptake. Such an artificial model
situation, in our understanding, cannot represent or reflect,
let alone predict the tumour visualization capacity of the
new compound in patients reliably, as the tissues surround-
ing spontaneously occurring pancreatic tumours in the
abdominal region often show high accumulation of radio-
tracers, e.g. due to excretion processes.
We assume that translation of preclinical animal data to
the clinic, apart from the inevitable species differences,
often fails due to avoidable quality problems, which parti-
ally depend on the field of research (e.g. disease models or
lack of comorbidities). If such shortcomings could be sys-
tematically assessed, we are convinced that the reliability of
preclinical in vivo data could be increased crucially. This
includes better design of animal models as well as higher
general study quality, such as blinding, randomization or
avoiding underpowered studies. Such improvements would
meet highest ethical standards, even if individual experi-
mental group sizes might be bigger.
Publication bias
In our opinion, a systematic status quo assessment of pre-
clinical animal research seems adequately achievable by
systematic reviewing and meta-analysis. Nevertheless,
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systematic reviewing and meta-analysis depend on the com-
plete availability of all research performed regarding a par-
ticular topic. As long as results are incompletely published,
systematic reviews and meta-analyses are liable to bias. This
bias is referred to as publication bias, i.e. favouring publi-
cation of positive or confirming data over negative or incon-
clusive data [23]. This overweighting of positive results
leads to a subsequent overestimation of effect sizes in
meta-analyses and systematic reviews. The publication bias
problem has been acknowledged in clinical research
[23–25]. In animal research, publication bias has been less
thoroughly investigated but there is evidence that research-
ers are becoming increasingly aware of it. In a recent pub-
lication, Sena and colleagues came to the conclusion that
publication bias accounts for one third of the effect in
animal stroke studies that was assessed in a systematic
review [26]. A Dutch research team recently tried to assess
the opinion amongst Dutch animal researchers and find
possible reasons for the publication bias phenomenon (ter
Riet et al., personal communication). Interestingly, journal
editors and peer reviewers were regarded as prominent drivers
for non-publication of negative or non-significant research
data. The authors suggest strategies to address publication
bias, such as mandatory publication of study protocols,
research results or the reasons why no results were obtained.
According to ter Riet and colleague’s study, Dutch researchers
think that these strategies might help to increase scientific
progress.
Conclusion
We believe that preclinical animal research needs to
improve on different levels to yield best predictions for
human patients. Animal models of diseases need to be as
reliably reflective of the patient’s situation as possible and
it should be considered to what extent experimental param-
eters need to be homogenized or if a controlled heteroge-
nization might be appropriate. Furthermore, general aspects
of experimental planning and performance should be
brought to a higher level. Regulatory authorities as well
as journal editors and peer reviewers should pay increasing
attention to features like sample size calculation, blinding
and randomization. And finally, efforts should be taken to
reduce publication bias in animal research literature to
increase the reliability of meta-analytic analysis of studies
in order to identify reasons for insufficient prediction of
models. Only if joint efforts are made is there hope that
preclinical animal research will yield safe and maximally
predictive results for the clinic. This concerns us all:
researchers in phases of experimental planning and per-
formance as well as regulatory authorities, journal editors
and peer reviewers.
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